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Abstract
Background: TAFI is a plasma protein assumed to be an important link between coagulation and
fibrinolysis. The three-dimensional crystal structures of authentic mature bovine TAFI (TAFIa) in
complex with tick carboxypeptidase inhibitor, authentic full lenght bovine plasma thrombin-
activatable fibrinolysis inhibitor (TAFI), and recombinant human TAFI have recently been solved. In
light of these recent advances, we have characterized authentic bovine TAFI biochemically and
compared it to human TAFI.
Results: The four N-linked glycosylation sequons within the activation peptide were all occupied
in bovine TAFI, similar to human TAFI, while the sequon located within the enzyme moiety of the
bovine protein was non-glycosylated. The enzymatic stability and the kinetic constants of TAFIa
differed somewhat between the two proteins, as did the isoelectric point of TAFI, but not TAFIa.
Equivalent to human TAFI, bovine TAFI was a substrate for transglutaminases and could be
proteolytically cleaved by trypsin or thrombin/solulin complex, although small differences in the
fragmentation patterns were observed. Furthermore, bovine TAFI exhibited intrinsic activity and
TAFIa attenuated tPA-mediated fibrinolysis similar to the human protein.
Conclusion: The findings presented here suggest that the properties of these two orthologous
proteins are similar and that conclusions reached using the bovine TAFI may be extrapolated to
the human protein.
Background
Human thrombin-activatable fibrinolysis inhibitor
(TAFI) (EC 3.4.17.20; UniProt, Q96IY4), also known as
plasma pro-carboxypeptidase B, R, and U, is a plasma
metallocarboxypeptidase that attenuates fibrinolysis [1-
10]. TAFI circulates in plasma as a 58 kDa protein with sig-
nificant intrinsic activity [11,12]. The majority of the sites
that undergo transglutaminase-mediated cross-linking to
Published: 5 May 2009
BMC Biochemistry 2009, 10:13 doi:10.1186/1471-2091-10-13
Received: 5 November 2008
Accepted: 5 May 2009
This article is available from: http://www.biomedcentral.com/1471-2091/10/13
© 2009 Valnickova et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 15
(page number not for citation purposes)
BMC Biochemistry 2009, 10:13 http://www.biomedcentral.com/1471-2091/10/13fibrin are primarily located on the heavily glycosylated
pro-peptide, suggesting that TAFI becomes incorporated
into the fibrin clot during later stages of the coagulation
cascade [13]. A variety of trypsin-like proteinases have
been shown to remove this peptide, generating the mature
protein, TAFIa [4,14-17]. The isoelectric point (pI) of this
proteolytically cleaved protein is around pH 8.5, which is
significantly more basic than that of TAFI (pI 5.5) [18].
TAFIa remains in circulation by forming complexes with
α2-macroglobulin and pregnancy zone protein [19] but is
highly unstable, a feature initially attributed to proteolytic
cleavage. However, this instability is now thought to
result from a temperature-dependent conformational
change that occurs within minutes of activation [4,20-22].
TAFI has been implicated not only in fibrinolysis, but also
in inflammation, wound healing, and a variety of other
deficiencies and diseases, such as diabetes, kidney failure,
lung cancer, and liver illnesses [23-29]. Interestingly, indi-
viduals with the more stable Ile325 variant are apparently
more susceptible to meningococcal sepsis [30]. TAFI has
been studied in multiple animal models, including dog,
rabbit, mouse, and rat [31-36]. Intriguingly, the absence
of the protein in knock out mice is compatible with
murine life [25,37,38].
Mouse and rat TAFI have been characterized, and both
show similarity to the human protein [32,33,35]. Until
very recently, the only available structural model for the
study of TAFI was human pancreatic pro carboxypeptidase
B (pro-CPB) [39]. The protein sequence of Pro-CPB is
about 40% identical to TAFI. However, in contrast to
TAFI, pro-CPB lacks intrinsic activity and its active form,
carboxypeptidase B (CPB), is stable upon activation [40].
Efforts to crystallize authentic human TAFI have been
unsuccessful, most likely due to its sugar heterogeneity
when purified from pooled plasma [18]. However, using
recombinant human TAFI and authentic protein purified
from a single cow enabled the zymogen structure to be
solved [41,42]. Although bovine TAFI is similar to pro-
CPB, it also has differences. Significantly, the position of
the pro-peptide is rotated 12° away from the active site,
exposing access to the catalytic residues. Another signifi-
cant distinction is the lack of the corresponding salt bridge
between Asp41 and Arg145 in TAFI [42]. These distinctions
might explain the intrinsic activity of TAFI [11,12]. Fur-
thermore, the structure of bovine TAFIa in complex with
tick carboxypeptidase inhibitor (TCI) was determined and
found to exhibit a high degree of identify with the CPB-
TCI structure [43-45]. Interestingly, the bovine TAFIa
structure contains two undefined regions, both of which
are part of exposed loops present in the Lβ2β3 and Lα2β4
regions and in a heparin affinity region [45]. The domains
including Arg302 and Arg330, which are predicted to cause
instability in human TAFI, were fully ordered in the
bovine molecule.
These recent advances prompted us to perform a thorough
biochemical characterization of the bovine protein, puri-
fied from bovine plasma. This biochemical characteriza-
tion included analysis of stability, N-linked glycosylation,
generation of TAFIa by removal of the pro-peptide by
trypsin and thrombin/solulin, the antifibrinolytic effects
of TAFIa, as well as analysis of the intrinsic activity of the
full length protein and its potential to become crosslinked
to fibrin by transglutaminases.
Results
Primary structure of bovine TAFI
The amino acid sequence of bovine TAFI was deduced
from a cDNA library and published recently [45]. The
sequence was 78.6% identical to that of the human pro-
tein. The bovine protein consisted of 401 amino acid res-
idues, including a 92-amino acid residue pro-peptide that
is released by cleavage at Arg92. All potential glycosylation
sites were conserved and found glycosylated in both spe-
cies, with exception of the fifth site (Asn219), which
remained unglycosylated in bovine TAFI. The location of
cysteine residues was identical in both species, with the
exception of Cys69. This cysteine residue, which is located
in the activation peptide, was absent from bovine TAFI. In
human TAFI, Cys69 does not form a disulfide bridge and
therefore, is unlikely to affect tertiary structure. All sites
involved in catalysis as well as substrate and zinc binding
were identical, suggesting that the two proteins have the
same proteolytic properties.
Generation and activity of TAFIa
SDS-PAGE of purified bovine TAFI produced a single
sharp band at around 56 kDa, which is slightly lower than
the position of human TAFI (Fig 1). TAFIa generated by
either trypsin (Fig 1A) or thrombin/solulin complex (Fig
1B) migrated at the same position for both species, sug-
gesting that differences in the migration of the full-length
species can be attributed to differences in carbohydrates
attached to the pro-peptide. It is obvious from the results
of the SDS-PAGE that greater amounts of proteinases were
required to generate human TAFIa (Fig 1). Since the
thrombin/solulin complex is considered to be responsible
for release of the TAFI pro-peptide in vivo [14] and since
trypsin seems to inactivate TAFIa more aggressively, only
the complex was used to determine the optimal condi-
tions for generation of bovine and human TAFIa. Increas-
ing amounts of the thrombin/solulin were incubated with
TAFI, and the enhanced activity was monitored by HPLC
based activity assay. As shown in Fig 1C, the amount of
proteinase complex required to achieve 100% TAFIa activ-
ity was much lower than that needed for the human TAFI.Page 2 of 15
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Generation of bovine and human TAFIaFigure 1
Generation of bovine and human TAFIa. Bovine and human TAFI (1 μg) were incubated with increasing amounts of 
trypsin (A) or thrombin/solulin complex (B) (all values in μg). Proteolysis products were then analyzed by SDS-PAGE and visu-
alized by Coomassie Brilliant Blue staining. Additionally, TAFI (0.2 μg of bovine or human) was incubated with increasing 
amounts of thrombin/solulin complex (C). Increase in activity of bovine (filled circles) and human (open circles) TAFIa was 
monitored through HPLC based kinetic assay using Hip-Arg substrate as described in the method section. Note that compared 
to human TAFI, roughly 15 times less proteinase complex is required to generate 100% active bovine TAFIa.
BMC Biochemistry 2009, 10:13 http://www.biomedcentral.com/1471-2091/10/13Furthermore, the kinetic constants for both species were
determined (Table 1). The intrinsic activity of TAFI is sim-
ilar between species, while the Vmax and Km for bovine
TAFa is somewhat higher in comparison to the human
protein.
Identification of proteolysis products generated upon 
proteinase addition to TAFI
The thrombin/solulin complex produced similar proteo-
lytic fragmentation in both the bovine and human TAFI.
The generated products were identified by Edman degra-
dation and are summarized in Table 2. SDS-PAGE of
bovine TAFI and thrombin/solulin mixture fashioned a
strong band not only at 56 kDa (corresponding to full
length TAFI), but also at 36 kDa, which was confirmed to
be TAFIa (Fig 2 and Table 2). In contrast to the human
TAFI pro-peptide, the released bovine pro-peptide was
clearly visible by Coomassie staining, with a mass of
around 29 kDa (Fig 2). As expected, large amounts of
thrombin/solulin complex truncated human TAFIa (36
kDa) at Arg302, liberating the 11.0 kDa C-terminal peptide
to produce a proteolytically inactivated form of TAFIa
(24.7 kDa) (Fig 1B). However, no further proteolytic
products were observed for the bovine protein in the
higher end of the titration using the proteinase complex.
When TAFI was cleaved by trypsin, which is more potent
than thrombin/solulin complex, a somewhat dissimilar
fragmentation pattern was generated (Fig 2). SDS-PAGE
of the human protein yielded a typical pattern consisting
of full length TAFI at 58 kDa, mature TAFIa at 36 kDa, C-
terminal processed TAFIa (through cleavage at Arg330) at
28 kDa, and the released C-terminal peptide at 8 kDa (Fig
2). Trypsin cleavage occurred at the same site in both the
human and bovine protein, creating a 36 kDa TAFIa
through truncation at Arg92 (Fig 2). Interestingly, in con-
trast to human TAFIa, bovine TAFIa was initially proteo-
lytically inactivated by cleavage at the N-terminus, rather
than the C-terminus. This processing occurred right after
Arg147, creating a 29.2 kDa fragment, detected around 32
kDa on SDS gel (Fig 2 and Table 2). The pro-peptide was
detected at around 29 kDa (Fig 2). However, it is most
likely immediately processed at the C-terminus, as a 25
kDa band was detected that also contained the TAFI N-ter-
minal sequence (Fig 2). Trypsin and small trypsin frag-
ments were also detected, along with the released 6.7 kDa
TAFIa N-terminal peptide (Fig 2 and Table 2).
Bovine TAFIa stability at 37°C
The thermal stability of TAFIa was investigated with HPLC
based kinetic assays using Hip-Arg as a substrate and the
thrombin/solulin complex as an activator (Fig 3). The
half-life of bovine TAFIa was longer than that of human
TAFIa. Human TAFIa activity decreased by 50% after 5
min, while this decrease in bovine TAFIa activity occurred
at 10 min (Fig 3).
Intrinsic activity of bovine TAFI
The intrinsic activity of the bovine protein was deter-
mined by activity assays using the Hip-Arg substrate and
compared to that of human TAFI, by measuring the
released hippuric acid by HPLC. TAFI activity was
undoubtedly detected using this method (Fig 4A). Moreo-
ver, hippuric acid release was blocked when TAFI was
incubated with the substrate in the presence of 5 mM 1,
10-phenantroline, a chelating agent and known carbox-
ypeptidase inhibitor (Fig 4B). This confirms that bovine
TAFI has genuine intrinsic activity. This activity was also
inhibited by 2.3 μM TCI, a potentially physiologically rel-
evant inhibitor of TAFI (Fig 4C).
Table 1: Summary of bovine and human TAFI and TAFIa kinetic values
Human TAFI Bovine TAFI Human TAFIa Bovine TAFIa
Equation* Vmax Km Vmax Km Vmax Km Vmax Km
Hanes 40.17 3.41 31.67 4.63 106.00 3.14 330.67 7.86
Eadie-Hofstee 43.00 3.96 32.50 4.65 113.33 3.68 332.00 7.84
Eisenthal-Cornish-Bowden 40.83 3.91 33.33 4.69 112.67 3.74 329.33 8.24
Hyperbolic Regression 41.33 ± 7.93 3.70 ± 1.51 33.40 ± 6.33 4.85 ± 2.50 106.67 ± 8.34 2.83 ± 0.89 326.67 ± 39.67 5.28 ± 1.96
Average values 41.33 3.75 32.73 4.71 109.67 3.35 329.67 7.31
Kcat (min-1) 243.12 192.53 4386.80 13186.80
Kcat/Km (min-1/mM) 64.83 40.88 1309.49 1803.94
*The values for Km and Vmax were determined by the direct fit of the Michaelis-Menten equation employing four graphical methods. The data 
represent the enzyme-catalysed reaction for 0.33 μM TAFI and 0.025 μM TAFIa.Page 4 of 15
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Isoelectric focusing revealed that the isoelectric point of
TAFI and TAFIa varied greatly in both species (data not
shown). The full length bovine protein migrated in the
lower end of the pH gradient and appeared as multiple
bands between a pI of 6.0 and 6.5, likely due to glycosyla-
tion heterogeneity. This migration position was slightly
higher than that of the human TAFI, which migrated to a
pI of 5.1 to 6.0 and also appeared as multiple isoforms.
Upon release of the heavily glycosylated activation pep-
tide, both human and bovine TAFIa appeared as a single
band at a much higher pI of around 8.5. Thus, the differ-
ence in migration between TAFI in the two species is due
to differences in the carbohydrate modifications to their
respective pro-peptides.
Bovine TAFI attenuates clot lysis in vitro
The effect of bovine TAFI on fibrinolysis was examined by
conducting a fibrinolyses assay in a purified system (Fig
5). The clot was generated in microtiter wells by addition
of thrombin to fibrinogen and the clot lysis initiated by
further addition of plasminogen and tPA simultaneously.
Purified bovine or human TAFI (1 μg) added to the wells,
in the presence and absence of solulin, was able to delay
clot lysis. Moreover, this effect was reversed by the carbox-
ypeptidase inhibitors, PCI or TCI, confirming capability
Identification of bovine TAFI products generated by proteolysisFigure 2
Identification of bovine TAFI products generated by proteolysis. SDS-PAGE of bovine or human TAFI (1 μg), which 
was cleaved using either 0.05 μg of trypsin, or thrombin/solulin complex in a ratio of 0.002 μg/0.05 μg. The products are indi-
cated with arrows and were identified by Edman-degradation (see Table 2 for a summary of the bovine TAFI products).
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shown).
Bovine TAFI is a substrate for tissue transglutaminase
To test whether bovine TAFI has the potential to become
cross-linked to a fibrin meshwork in the same manner as
the human protein, we monitored the incorporation of a
fluorescent donor, dansylcadaverine, into the protein by
tissue transglutaminase. Visualization of SDS-polyacryla-
mide gels with UV light revealed that both human TAFI
and α-2AP (another known tissue transglutaminase sub-
strate) incorporated dansylcadaverine (Fig 6). Impor-
tantly, dansylcadaverine was also successfully
incorporated into bovine TAFI under these conditions,
showing that bovine TAFI can serve as a transglutaminase
substrate.
Bovine TAFI contains four N-linked carbohydrate 
structures, which are located solely on the activation 
peptide
To characterize the glycans of bovine TAFI, we performed
tryptic digests with and without subsequent PNGase F
treatment, and separated the resulting fragments using
RP-HPLC. Fractions containing glycopeptides were puri-
fied and analyzed using MALDI-TOF MS and subse-
quently verified based on their fragmentation using
MALDI quadrupole (Q) TOF MS/MS (data not shown).
Thirty-five N-glycans were observed from the four N-glyc-
osylation sites present within the N-terminal activation
region (i.e., N22, N51, N63, and N86) (Fig 7 and Table 3).
Biantennary structures without core fucosylations were
the sole structures identified by the glycoanalysis. Hence,
the substantial microheterogeneity observed was limited
to variations in the contents of the two types of sialic
acids, N-glycolylneuraminic acid (Neu5Gc) and N-acetyl-
neuraminic acid (Neu5Ac). Up to four sialic acid residues
were observed on the N22 glycans, whereas the rest of the
occupied sequons contained a maximum of three sialic
acid residues (Fig 7). Peptide mass fingerprinting of tryp-
tic bovine TAFI treated with and without PNGase F
revealed that neither of the two potential sites located in
the middle of the protein (N219 and N226) was occupied
by N-glycans. In contrast, N-linked glycosylation has been
detected in human TAFIa. The human protein also exhib-
its a much greater heterogeneity in the N-linked sugars
[18]. This may help account for difficulties in determining
the three-dimensional structure of human TAFI zymogen.
Discussion
The structure of TAFI and TAFIa/TCI complex has recently
been solved using authentic bovine TAFI [42,45]. Here,
we present a full biochemical characterization of the
bovine protein purified from bovine plasma. The amino
acid sequence idenity between the two spieces is 78.6%
and all the important sites, such as the catalytic domain,
substrate-binding domain, and zinc-binding domain, are
fully conserved [45]. Only four of the potential N-linked
carbohydrate sites are occupied, all located on the activa-
tion peptide. The fifth site, Asn219, which is partially glyc-
osylated in the human protein [18], remained
Table 2: Summary of bovine TAFI activation products
Product** Proteinase used
in activation
SDS-PAGE
mass (kDa)
Theoretical mass (kDa) N-terminal sequence*
Bovine TAFI zymogen N/A
(full length TAFI)
56 46.4 FQRGVLSALP
Bovine TAFIa trypsin
solulin/thrombin
36 35.9 ASSSYYEQYH
Bovine TAFIa
cut at the
n-terminus
trypsin 32 29.2 AKNAMWID
Bovine TAFI
activation peptide
trypsin
solulin/thrombin
29 10.5 FQRGVLSALP
Bovine TAFI
activation peptide
trypsin 25 NA FQRGVLSALP
Bovine TAFIa
N-terminal peptide
trypsin <6 6.7 ASSSYYEQYH
*Determined by Edman Degradation.
**Upon cleavage of bovine TAFI by either trypsin or solulin/thrombin complex, fragments were separated by SDS-PAGE, transferred to PVDF 
membrane and subjected to Edman –degradation as described in the method section. The obtained n-terminal sequences of fragments and their 
molecular weight is listed.Page 6 of 15
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this site was found to be buried within the protein struc-
ture and has previously been suggested to be unglyco-
sylated [42]. Recently, the biochemical importance of
human TAFI glycosylation has been studied using TAFI
mutants [46]. Interestingly, in some mutants, the absence
of carbohydrates increases the activity of full length TAFI,
but decreases TAFIa activity. The increase in intrinsic activ-
ity is most apparent in the mutants TAFI-N22Q and TAFI-
N22Q-N51Q-N63Q. These observations corroborate the
finding that, in human TAFI, access to the active site exists
[11] and this access site potentially expands upon carbo-
hydrate removal, possibly imparting a catalytic function
to sugars [46].
Interestingly, the pronounced microheterogeneity of the
TAFI glycans was exclusively generated by the variation in
the number and type of sialic acid residues located in the
termini of the biantennary complex glycans. Neu5Ac and
Neu5Gc were found in the TAFI glycans and both are
known to be abundant sialic acids in bovine glycoconju-
gates. In contrast, humans cannot synthesize Neu5Gc,
highlighting a difference between the authentic human
and authentic bovine TAFI structure.
Purified bovine TAFI successfully attenuated fibrinolysis
of tPA-induced clots in a purified system. Also similar to
human TAFI, the bovine protein displays considerable sta-
ble intrinsic activity, which can be abolished by the same
inhibitors used to inhibit TAFIa. Furthermore, it is most
likely crosslinked to the fibrin meshwork during the early
stages of fibrinolysis, as the protein seems to act as a sub-
strate for transglutaminases. Bovine TAFI contains poten-
tial amine acceptor sites, as evidenced by the successful
incorporation of dansylcadavarine into the protein by tis-
sue transglutaminase.
Bovine TAFI, like the human protein, can also be cleaved
through proteolysis at Arg92, generating the mature form,
TAFIa. In contrast to the human TAFI, bovine TAFI is proc-
essed into not only the 36 kDa active enzyme, but also a
29 kDa TAFIa fragment following incubation with trypsin.
This N-terminally processed TAFIa is missing a 7 kDa N-
terminal peptide and is formed through proteolysis of the
Arg147-Ala148 bond. This cleavage takes place prior to the
usual inactivation that occurs at the C-terminus. Human
TAFI contains either a Thr or Ala at position 147, depend-
ing on the variant. Therefore, an identical N-terminal
truncation at this position is not possible [47]. Similar
fragmentation has been observed following activation of
rat TAFI by plasmin [35]. This may also explain the disor-
dered Lβ2β3 segment observed in the three-dimensional
structure of the TAFIa/TCI complex [45].
In human TAFI, substituting His333 with Tyr or Gln
increases the half-life of TAFIa for up to 1.5 h, while pre-
serving all characteristics of wild type TAFI [48]. Site-
directed mutagenesis of Arg302, Arg320, and Arg330 pro-
duces a molecule much less stable than the wild type pro-
tein, suggesting that this instability is concentrated in the
302 – 330 region [21,49]. The naturally occurring muta-
tion of Thr325 to Ile325 has been shown to make human
TAFI twice as stable [21,50,51]. Position 325 of the bovine
protein is occupied by Ile, which might account for the
longer half-life of bovine TAFIa (10 min) compared to the
human TAFIa (5 min). Similarly, mutation of Thr329 to
Ile329 increases not only the half-life of the cleaved human
protein, but also its fibrinolytic effect [21]. Again, this
position is occupied by Ile in bovine TAFI.
Substitution of human TAFI residues with corresponding
residues of CPB, such as TAFIa-Ile182Arg-Ile183Glu, does
not significantly increase stability. On the contrary, it
reduces antifibrinolytic potential. Nevertheless, lower
amounts of thrombin-thrombomodulin complex are
Bovine TAFIa is more stable at 37°C than human TAFIaFigur  3
Bovine TAFIa is more stable at 37°C than human 
TAFIa. Bovine (filled circles) or human (open circles) TAFI 
(3 μg of each) were added thrombin/solulin complex (using 
optimal conditions as determined in the method section), 
placed at 37°C, and subjected to HPLC based kinetic assays 
using Hip-Arg substrate at the indicated intervals. Bovine 
TAFIa is more stable than human TAFIa, as seen by a half-life 
that is twice as long (i.e., 10 min vs. 5 min).Page 7 of 15
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This can explain, at least partly, why lower amounts of
proteinases are required to generate bovine TAFIa, in
which Lys182 and Glu183 naturally occur in sequence.
Indeed, 15 times less solulin/thrombin complex is
required to generate bovine TAFIa with activity similar to
that of human TAFIa.
In summary, we deduce that human TAFI and bovine TAFI
have similar properties. The overall secondary structure is
conserved, generation of TAFIa can be achieved in similar
manner, and bovine TAFIa produces a measurable effect
on fibrinolysis. Thus, the available three-dimensional
structure of bovine TAFI is a reliable model for investiga-
tion of human TAFI, including its in vivo function and the
in vivo effects of its inhibition.
Conclusion
The bovine and human TAFI activation occurs at equiva-
lent sites and both TAFIa and TAFI exhibit caroboxypepti-
dase activity. Additionally, TAFI from both species was
found to be substrate for transglutaminases. Minor differ-
ences in the enzymatic stability of bovine and human
TAFIa was observed as well as differences in the level of
glycosylation, isoelectric point and proteolytic by-prod-
ucts in trypsin activation. However, overall the findings
suggested that the the two orthologous proteins are simi-
lar and that conclusions reached using the bovine TAFI
can safely be extrapolated to the human protein.
Methods
Materials
Bovine trypsin, 1, 10-phenantroline, phenylmethylsulfo-
nyl fluoride (PMSF), polyethylene glycol 8000 (PEG), and
the chromogenic carboxypeptidase substrate, hippuryl-
Arg (Hip-Arg), were obtained from Sigma. Ortho-methyl-
hippuric acid and Pefablock SC were from Aldrich. ECH-
Lysine Sepharose was from Amersham Biosciences, GE
Healthcare (Uppslala, Sweden). Dansylcadaverine was
from Molecular Probes (Eugene, OR).
Proteins
Human TAFI and human α2-antiplasmin (α-2AP) were
purified from normal human plasma (Statens Serum,
Bovine TAFI cleaves Hip-Arg substrateFigur  4
Bovine TAFI cleaves Hip-Arg substrate. The intrinsic activity of the bovine and human protein (1 μg) was investigated by 
incubating TAFI with Hip-Arg substrate in the absence (A) or presence of 5 mM 1, 10-phenantroline (B) or 1 μg TCI (C). The 
cleaved product, hippuric acid (1), was then separated from the internal standard (2) by RP-HPLC. Bovine TAFI, similar to 
human TAFI, produces considerable hippuric acid, and this carboxypeptidase activity is abolished by addition of either 1, 10-
phenantroline or TCI.Page 8 of 15
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depleted plasma and plasminogen-Sepharose affinity
chromatography as described previously [4,18]. Guinea
pig liver (tissue) transglutaminase (EC 2.3.2.13), human
fibrinogen and human thrombin (EC 3.4.21.5) were pur-
chased from Sigma. Recombinanat tPA (EC 3.4.21.68)
was purchased from ProSpec-Tany TechnoGene LTD.,
Rehovot, Israel. Recombinant soluble thrombomodulin
(solulin) was a generous gift of Dr. Achim Schuettler
(PAION GmbH, Aachen, Germany) and Factor XIIIa from
Sanofi-Aventis. Potato carboxypeptidase inhibitor (PCI)
and TCI were kind gifts from Prof. Francesc. X. Aviles, Dr.
Joan Lopez Arolas, and Dr. Laura Sanglas. TAFI-antiserum
was raised commercially (Pel-Freez, Rogers, AR). Human
plasminogen was purified by affinity chromatography
using ECH-Lysine Sepharose as described previously [53].
Purification of bovine TAFI
Bovine TAFI was purified essentially as already described
[45]. In short, bovine blood (10 L) was collected at the
local slaughterhouse and supplemented with 5 mM EDTA
to prevent coagulation. The plasma was separated from
erythrocytes by centrifugation at 600 × g for 15 min at
22°C. Plasma was incubated with 6% (w/v) PEG, and
after 1 h, the precipitated proteins were removed by cen-
trifugation at 10,000 × g for 40 min at 4°C. Plasminogen
was removed from the supernatant by affinity chromatog-
raphy using 1 L of ECH-Lysine Sepharose equilibrated in
binding buffer (50 mM NaH2PO4, pH 7.5 and 100 mM
NaCl). Plasminogen-depleted plasma was applied to a
500-ml plasminogen Sepharose column equilibrated in
binding buffer, and bovine TAFI was eluted using 50 mM
γ-amino-caproic acid. After buffer exchange into 20 mM
Tris-Cl (pH 7.5), bovine TAFI was separated from other
contaminants by ion-exchange chromatography on a 5-
ml HiTrapQ column connected to an AKTA Prime system
(Amersham Biosciences, GE Healthcare). The column was
eluted, at a flow rate of 1 ml/min, using a 0.5%/min linear
gradient of Buffer A (20 mM Tris-Cl, pH 7.5) and Buffer B
(20 mM Tris-Cl, pH 7.5 containing 1 M NaCl).
Polyacrylamide gel electrophoresis
Proteins were separated by SDS-PAGE in 5 – 15% polyacr-
ylamide gels [54]. Samples were boiled for 5 min in the
presence of 30 mM dithiothreitol (DTT) and 1% SDS
prior to electrophoresis.
Generation of human and bovine TAFIa
Human and bovine TAFI (1 μg) were incubated with
increasing amounts of the thrombin/solulin complex, (0
μg/0 μg to 0.01 μg/0.25 μg) for 30 min at 22°C in 20 mM
Tris-HCl and 100 mM NaCl, pH 7.5. For trypsin induced
proteolysis, 1 μg TAFI (human and bovine) was incubated
with increasing amounts of trypsin (0–0.5 μg) for 20 min
at 37°C in 20 mM Tris-HCl and 100 mM NaCl, pH 7.5. All
reactions were terminated by addition of Pefablock or
PMSF to a final concentration of 5 mM. Optimal condi-
tions to generate TAFIa with peak activity were deter-
mined through kinetic assays (using 0.2 μg of TAFI) and
SDS-PAGE (using 1.0 μg TAFI) with the physiologically
relevant thrombin/solulin complex as an activator only.
To activate 1 μg of human TAFI, the optimal trombin/
solulin complex ratio (w/w) was 0.06 μg/1.5 μg. Genera-
tion of bovine TAFIa was optimal using thrombin/solulin
complex ratio of 0.004 μg/0.1 μg to 1 μg TAFI.
NH2-terminal amino acid sequencing
Proteolytic fragments of bovine TAFI generated by trypsin
or solulin/thrombin complex were separated by SDS/
PAGE. The stacking gel was allowed to polymerize one
day prior to electrophoresis, and samples were heated for
3 min at only 80°C prior to separation. After electro-
phoresis, proteins were transferred to a polyvinylidene
difluoride membrane (Immobilon-P, Millipore) in 10
mM CAPS and 10% (v/v) methanol (pH 11) [55]. Alter-
natively, the TAFI-trypsin or TAFI-solulin/thrombin mix-
ture was applied to an activated ProSorb sample
preparation cartridge (Applied Biosystems), according to
the manufacturer's instructions. Samples were analyzed
by automated Edman degradation using an Applied Bio-
systems PROCISE™ 494 HT sequencer with on-line HPLC
Bovine TAFIa attenuates clot lysisFigur  5
Bovine TAFIa attenuates clot lysis. The anti fibrinolytic 
function of bovine TAFIa was tested and compared to that of 
human TAFIa in a purified system. Clott formation was initi-
ated by addition of thrombin to fibrinogen in the presence of 
CaCl2. Simultaneously, the dissolution of clot was generated 
by tPA and plasminogen addition. The change in turbidity was 
monitored at 405 nm (crosshairs). Upon addition of 1 μg of 
either bovine TAFI (filled circles) or human TAFI (filled 
squares), in the presence of Solulin, a delay in clot lysis was 
observed. A small anti fibrinolytic effect was observed upon 
addition of 1 μg of bovine TAFI (open circles) and human 
TAFI (open squares) in the absence of Solulin as well.Page 9 of 15
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toin analysis.
Isoelectric focusing
Isoelectric focusing of bovine TAFI was performed essen-
tially as described previously [18]. Briefly, 10 μg of salt-
free protein was focused under native conditions in a
Ready IEF gel using the MiniProtean III Cell (Biorad)
according to the manufacturer's instructions. Bands were
focused in a pH gradient of 3 – 10 using 20 mM lysine and
20 mM arginine as a cathode buffer and 7% phosphoric
acid as anode buffer (all in H2O). Running conditions
consisted of 100 V for 60 min, 250 V for 60 min, and 500
V for 30 min. Bands were visualized using IEF staining
solution (27% isopropyl alcohol, 10% acetic acid, 0.04%
Coomassie Blue R250, and 0.05% Crocein Scarlet in
H2O).
HPLC based kinetic activity assay using Hip-Arg substrate
The activity of both full length and mature TAFI was deter-
mined essentially as described previously [56]. A 10-μl
sample containing 1 μg of bovine TAFI or 0.2 μg TAFIa
was incubated with 40 μl of 30 mM Hip-Arg for 40 min.
Some samples were incubated for 15 min with 5 mM
phenanthroline or 1 μg TCI prior to substrate addition.
The reactions were stopped by addition of 50 μl 1 M HCl.
Ten microliters of 15 mM ortho-methylhippuric acid was
included in the reaction mixture as an internal standard.
The reaction products, as well as the internal standard,
were extracted using 300 μl ethyl acetate. One-hundred
microliters of the extracted sample were lyophilized, solu-
bilized in 100 μl mobile phase buffer [10 mM KH2PO4,
pH 3.4 containing 15% acetonitrile (ACN)], and sepa-
rated on a reverse phase (RP) HPLC column (PTH C18, 5
μm, 220 × 2.1 mm, Applied Biosystems) using the ÄKTA
Ettan system (Amersham Biosciences, GE Healthcare).
Determination of TAFI kinetic constants
Human and bovine TAFI kinetic properties were essen-
tially determined as described previously, with small
modifications [46]. Briefly, 1 μg of the zymogen and 0.1
μg of TAFIa, generated by the thrombin/solulin complex,
for both human and bovine protein, were incubated with
increasing concentration of the Hip-Arg substrate (0–30
mM), in duplicates, for 60 min at 37°C in a final volume
of 60 μl. The reaction was terminated by addition of 20 μl
1 M HCl, neutralized by addition of 20 μl of 1 M NaOH
and buffered with 25 μl of 1 M NaH2PO4, pH 7.4. Upon
addition of 60 μl 6% cyanuric chloride dissolved in 1,4-
dioxane, the samples were vortexed vigorously and centri-
fuged at 16000 × g for 5 minutes. The supernatant was
subsequently transferred to 96-well microtiter plate and
the absorbance was measured at 405 nm in a FLUOStar
Omega plate reader (BMG Labtech) using the endpoint
mode. The kinetic constants were determined using 4 dif-
ferent graphical methods.
Thermal stability of TAFIa enzymatic activity
Bovine and human TAFI (3 μg) were mixed with solulin/
thrombin complex using the optimal conditions for gen-
eration of TAFIa for each species. At the time of reaction
termination with pefablock (5 mM final concentration),
the reaction mixture was placed at 37°C. At various inter-
vals over 120 min, 0.2 μg of TAFI protein was removed
Bovine TAFI is a substrate for transglutaminasesFigur  6
Bovine TAFI is a substrate for transglutaminases. 
Bovine TAFI (2 μg) was incubated with increasing amounts of 
tissue transglutaminase (TG), in the presence of the fluores-
cent donor, dansylcadaverine. The reaction products were 
separated by SDS-PAGE and visualized under UV light. 
Human TAFI (2 μg) and α2-antiplasmin (2 μg) served as a 
controls. Note the clear incorporation of dansylcadavarine 
into bovine TAFI, suggesting that it contains amine acceptor 
sites and functions as a substrate for transglutaminases.
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ments were then performed using HPLC method
described above.
In vitro clot lysis assays
Clot lysis assays were performed essentially as described
previously [57] using 96-well microtiter plates, with some
modifications. Twenty μl of fibrinogen (20 μl/μg), 1 μl of
plasminogen (0.5 μg/μl) and 12.5 μl of factor XIIIa (0.8
μg/μl) were mixed in a final volume of 100 μl in 20 mM
Hepes and 150 mM NaCl, 5 mM CaCl2, pH 7.4 (reaction
buffer) in a set of wells. In a proximate set of wells, 1 μl of
tPA (0.002 μg/μl) and 2 μl of thrombin (20 U/ml) were
combined in a final volume of 50 μl using the reaction
buffer. Clotting was initiated by addition of 50 μl of the
fibrinogen/plasminogen/factor XIIIa mixture to wells
containing tPA and thrombin. In some wells, 10 μl of
solulin (0.1 μg/μl) was added to the tPA/thrombin mix-
ture prior to clot initiation. Purified human or bovine
TAFI (1 μg), was added to certain wells containing tPA,
thrombin and (+/-) solulin, moments prior to the start of
the clotting generation. Some wells contained addition-
ally 1.27 μM TCI or 4.65 μM PCI. The turbidity of the clot
was measured continuously at 405 nm in a plate reader
(FLUOstar Omega, BMG LABTECH GmbH) at 37°C. The
lysis time was defined as the time required for a 50%
reduction in optical density.
Incorporation of dansylcadaverine using tissue 
transglutaminase
Human TAFI, bovine TAFI, or α-2AP (2 μg of each) were
incubated with varying amounts of tissue transglutami-
nase (0 – 2 μg) for 3 h at 37°C in 20 mM Tris-Cl and 100
mM NaCl (pH 7.5) containing 10 mM Ca2+, 0.5 mM DTT,
and 0.5 mM dansylcadaverine. The reaction was stopped
by addition of 10 mM EDTA, and samples were analyzed
by reducing SDS-PAGE. The gel was visualized under UV
light.
Amino acid sequence analysis
To determine the accurate concentration of TAFI used in
this study, we performed each analysis in triplicate. For
each analysis, approximately 2 μg of purified bovine or
human TAFI was dried in 500 μl polypropylene vials. The
lids were punctured, and the vials were placed in a 25-ml
glass vial equipped with a MinInert valve (Pierce Biotech-
nology, Rockford, IL, USA). Two-hundred microliters of 6
N HCl containing 0.1% phenol was placed in the bottom
of the glass and blown with argon before a vacuum was
applied. The samples were incubated at 110°C for 18 h.
They were subsequently redissolved in 50 μl 0.20 M
sodium citrate loading buffer, pH 2.20 (Biochrom, Cam-
bridge, UK), transferred to microvials, and loaded on a
BioChrom 30 amino acid analyzer (Biochrom). Data
analysis was performed using software developed in
house.
Proteolytic digestion of bovine TAFI and purification of 
glycosylated peptides
Modified trypsin (2 μg, Promega, Madison, WI) was
added to approximately 40 μg of purified bovine TAFI in
20 mM Tris and 200 mM NaCl (pH 7.5) and then incu-
bated overnight at 37°C. The resulting peptide mixture
was split into two samples. N-glycosidase F (1 U, Roche,
Mannheim, Germany) was added to one of the samples
and incubated overnight at 37°C. The other sample was
stored at -18°C. The two samples were applied separately
to a reversed phase HPLC column (Jupiter C18 250 mm ×
N-glycans of bovine TAFIFigure 7
N-glycans of bovine TAFI. The site in the N-terminal sequence which is cleaved, releasing the pro-peptide (Arg92) and 
known disulfide bonds of bovine TAFI are shown in the schematic, as well as the glycosylation sites (not drawn to scale). 
Square brackets indicate that the glycans were observed with and without the particular carbohydrate residue. (Filled squares, 
N-acetylglucosamine; Open circles, mannose; Filled circles, galactose; Filled diamonds, 5-N-acetylneuraminic acid; Open dia-
monds, 5-N-glycolylneuraminic acid).
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Table 3: Structure of N-linked carbohydrates in bovine TAFI
Site N-Glycans/Occupancy** Observed glycopeptide 
mass (Da)
Theoretical glycopeptide 
mass (Da)
Glycan mass (Da) Glycans***
N22 Yes/100% 3157.2 3157.4 1622.6 Gal2Man3GlcNAc4
3448.3 3448.5 1913.7 Neu5Ac1Gal2Man3GlcNAc4
3464.3 3464.5 1929.7 Neu5Gc1Gal2Man3GlcNAc4
3739.5 3739.6 2204.8 Neu5Ac2Gal2Man3GlcNAc4
3755.5 3755.6 2220.8 Neu5Gc1Neu5Ac1Gal2Man3Gl
cNAc4
4030.6 4030.7 2495.9 Neu5Ac3Gal2Man3GlcNAc4
4046.7 4046.7 2511.9 Neu5Gc1Neu5Ac2Gal2Man3Gl
cNAc4
4062.6 4062.7 2527.9 Neu5Gc2Neu5Ac1Gal2Man3Gl
cNAc4
4321.8 4321.8 2787.0 Neu5Ac4Gal2Man3GlcNAc4
4337.8 4337.8 2803.0 Neu5Gc1Neu5Ac3Gal2Man3Gl
cNAc4
4353.8 4353.8 2819.0 Neu5Gc2Neu5Ac2Gal2Man3Gl
cNAc4
N51 Yes/100% 3533.6 3533.5 1622.6 Gal2Man3GlcNAc4
3824.7 3824.6 1913.7 Neu5Ac1Gal2Man3GlcNAc4
3840.7 3840.6 1929.7 Neu5Gc1Gal2Man3GlcNAc4
4115.9 4115.7 2204.8 Neu5Ac2Gal2Man3GlcNAc4
4131.9 4131.7 2220.8 Neu5Gc1Neu5Ac1Gal2Man3Gl
cNAc4
4407.1 4406.8 2495.9 Neu5Ac3Gal2Man3GlcNAc4
4423.1 4422.8 2511.9 Neu5Gc1Neu5Ac2Gal2Man3Gl
cNAc4
4439.1 4438.8 2527.9 Neu5Gc2Neu5Ac1Gal2Man3Gl
cNAc4
N63 Yes/100% 2389.9 2390.0 1622.6 Gal2Man3GlcNAc4
2681.0 2681.1 1913.7 Neu5Ac1Gal2Man3GlcNAc4
2697.0 2697.1 1929.7 Neu5Gc1Gal2Man3GlcNAc4
2972.1 2972.2 2204.8 Neu5Ac2Gal2Man3GlcNAc4
2988.0 2988.2 2220.8 Neu5Gc1Neu5Ac1Gal2Man3Gl
cNAc4
3263.3 3263.3 2495.9 Neu5Ac3Gal2Man3GlcNAc4
3279.2 3279.3 2511.9 Neu5Gc1Neu5Ac2Gal2Man3Gl
cNAc4
3295.3 3295.3 2527.9 Neu5Gc2Neu5Ac1Gal2Man3Gl
cNAc4
N86 Yes/100% 2851.0 2851.2* 1622.6 Gal2Man3GlcNAc4
3142.1 3142.3* 1913.7 Neu5Ac1Gal2Man3GlcNAc4
3158.1 3158.3* 1929.7 Neu5Gc1Gal2Man3GlcNAc4
3433.2 3433.4* 2204.8 Neu5Ac2Gal2Man3GlcNAc4
3449.2 3449.4* 2220.8 Neu5Gc1Neu5Ac1Gal2Man3Gl
cNAc4
3724.3 3724.5* 2495.9 Neu5Ac3Gal2Man3GlcNAc4
3740.4 3740.5* 2511.9 Neu5Gc1Neu5Ac2Gal2Man3Gl
cNAc4
3756.4 3756.5* 2527.9 Neu5Gc2Neu5Ac1Gal2Man3Gl
cNAc4
N219 unglycosylated
N226 unglycosylated
*Theoretical glycopeptide mass values are based on the transformation of the N-terminal Gln82 to pyroglutamic acid.
**Percent occupancy of N-glycans was determined based on MS experiments in which peptide mass fingerprints of tryptic bovine TAFI treated ± PNGase F were 
compared to establish the presence of (non/de)-glycosylated peptides (data not shown).
***GlcNAc, N-acetylglucosamine; Man, mannose; Gal, galactose; Neu5Ac, 5-N-acetylneuraminic acid; Neu5Gc, 5-N-glycolylneuraminic acid.
BMC Biochemistry 2009, 10:13 http://www.biomedcentral.com/1471-2091/10/132 mm, 5 μm, 300 Å, Phenomenex, Torrance, CA) con-
nected to an ÄKTA Basic instrument (Amersham Pharma-
cia Biotech, GE, Uppsala, Sweden). The sample was
applied in buffer A [0.06% trifluoroacetic acid (TFA) in
water] and eluted using the following three-step gradient
in buffer B (0.05% TFA and 90% ACN in water): 5 to 40%
in 30 min, 40 to 60% in 5 min, and 60 to 90% in 3 min.
Differences in the corresponding chromatograms revealed
the fractions potentially containing glycopeptides. These
fractions were dried and redissolved in 5% formic acid for
further analysis.
Characterization of glycosylated peptides by matrix-
assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS)
The fractions containing glycopeptides were concentrated
and desalted using hydrophobic microcolumns packed
with Poros R2 (20 μm, Applied Biosystems, Framingham,
MA) in GelLoader pipette tips (Eppendorf, Hamburg, Ger-
many) as described elsewhere [58]. The samples were
eluted directly onto the MS target with 0.5 μl 2,5-dihy-
droxybenzoic acid (20 g/L) in 70% ACN and 0.1% TFA.
Alternatively, fractions were not desalted and analyzed by
mixing 0.5 μl sample and 0.5 μl matrix directly on the tar-
get. All samples were analyzed in positive polarity mode
by MALDI MS using a Bruker Ultraflex (Bruker Daltonics,
Bremen, Germany) with TOF-TOF technology or a MALDI
Q-TOF Ultima (Waters, Micromass, Manchester, UK). The
spectra were internally calibrated, or external calibration
was performed by placing a tryptic lactoglobulin digest
near the actual target spot.
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